A macrophage-nanozyme delivery system for Parkinson's disease

被引:175
作者
Batrakova, Elena V. [1 ]
Li, Shu
Reynolds, Ashley D.
Mosley, R. Lee
Bronich, Tatiana K.
Kabanov, Alexander V.
Gendelman, Howard E.
机构
[1] Univ Nebraska Med Ctr, Ctr Drug Delivery & Nanomed, Omaha, NE 68198 USA
[2] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA
[3] Univ Nebraska Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE USA
[4] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
[5] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia
关键词
D O I
10.1021/bc700184b
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEIPEG). The self-assembled catalase/PEI-PEG complexes, "nanozymes", were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, "naked" catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-intoxicated mice, ca. 0.6% of the injected dose were found in brain. We conclude that cellmediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.
引用
收藏
页码:1498 / 1506
页数:9
相关论文
共 99 条
[1]
Abraham S, 2005, INDIAN J MED RES, V121, P111
[2]
ALLISON A C, 1974, P419
[3]
BRAIN PEROXIDASE AND CATALASE IN PARKINSON DISEASE [J].
AMBANI, LM ;
VANWOERT, MH ;
MURPHY, S .
ARCHIVES OF NEUROLOGY, 1975, 32 (02) :114-118
[4]
Anthony D C, 2001, Prog Brain Res, V132, P507
[5]
Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats [J].
Anthony, DC ;
Bolton, SJ ;
Fearn, S ;
Perry, VH .
BRAIN, 1997, 120 :435-444
[6]
Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model [J].
Aoki, H ;
Kakinuma, K ;
Morita, K ;
Kato, M ;
Uzuka, T ;
Igor, G ;
Takahashi, H ;
Tanaka, R .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2004, 20 (06) :595-605
[7]
Brain-derived neurotrophic factor is neuroprotective against human immunodeficiency virus-1 envelope proteins [J].
Bachis, A ;
Mocchetti, I .
NEUROPROTECTIVE AGENTS, 2005, 1053 :247-257
[8]
Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations [J].
Banks, WA .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (10) :801-809
[9]
Strategies for the delivery of leptin to the CNS [J].
Banks, WA ;
Lebel, CP .
JOURNAL OF DRUG TARGETING, 2002, 10 (04) :297-308
[10]
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery [J].
Batrakova, EV ;
Vinogradov, SV ;
Robinson, SM ;
Niehoff, ML ;
Banks, WA ;
Kabanov, AV .
BIOCONJUGATE CHEMISTRY, 2005, 16 (04) :793-802